RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1424 participants.

Also called NCT06195540

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,424 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06195540
  • EU CT 2023-509905-62-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
France (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06195540. Randomized; single masking; primary purpose prevention. Start 2024-07-19 (actual); primary completion 2028-11-19 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
Acronym
RIVACAST
Condition
Venous Thromboembolism
Condition
Lower Limb Trauma
Condition
Thromboprophylaxis
Condition
Immobilisation
Intervention (Drug)
Rivaroxaban 10 MG
Intervention (Drug)
Low Heparin Molecular Weight
Lead sponsor
University Hospital, Angers (class: other government)

Record details

Record id
cardio:ct-nct06195540
Content hash
02252d225a7115c5d0101154769ba08af7e4356e1bb60bc7000940cce165dfe1